Head-to-Head

Bolt Biotherapeutics, Inc. Common Stock vs. Eli Lilly & Co.

BOLT

Bolt Biotherapeutics, Inc. Common Stock

$3.56 +6.43%

VS LLY

Eli Lilly & Co.

$1159.07 +0.53%

Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.

Size & Scale

BOLTLLY
Market Cap $6.86 million $1.03 trillion
Revenue (TTM) $4.70 million $79.67 billion
Net Income (TTM) $-28,739,000 $26.71 billion

LLY leads on 3 of 3 size & scale factors.

Valuation

BOLTLLY
P/E Ratio — 38.91
Price / Book 0.54 30.33
Price / Sales 1.46 12.90

BOLT leads on 2 of 2 valuation factors.

Profitability

BOLTLLY
Net Margin -611.47% 33.53%
Return on Equity -227.37% 78.84%

LLY leads on 2 of 2 profitability factors.

Dividend

BOLTLLY
Dividend Yield — 0.60%
Payout Ratio — 23.23

BOLT and LLY split the dividend factors evenly.

Risk & Sentiment

BOLTLLY
Short Interest 22.62% 1.29%

LLY leads on 1 of 1 risk & sentiment factors.

Dig deeper: BOLT overview, BOLT financials, LLY overview, LLY financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.